Uptravi

Pulmonary Arterial Hypertension

Treatment

2 FDA approvals

0 Active Studies for Uptravi

What is Uptravi

Selexipag

The Generic name of this drug

Treatment Summary

Selexipag, sold under the brand name Uptravi, is a medication used to treat pulmonary arterial hypertension (PAH). It was approved by the FDA in 2015 and works by increasing the blood vessels that supply blood to the lungs, leading to increased blood flow and reduced pressure. Selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to achieve this effect. It is used to delay the progression of PAH and reduce the risk of hospitalization.

Uptravi

is the brand name

image of different drug pills on a surface

Uptravi Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Uptravi

Selexipag

2015

11

Approved as Treatment by the FDA

Selexipag, otherwise known as Uptravi, is approved by the FDA for 2 uses such as Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) and Pulmonary Arterial Hypertension .

Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

Helps manage Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

Pulmonary Arterial Hypertension

Helps manage Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

Effectiveness

How Uptravi Affects Patients

Selexipag has been tested to make sure it does not have a harmful effect on the heart's rhythm. It has been seen to inhibit platelet aggregation in a laboratory setting, but does not seem to have an effect on platelet aggregation when taken at normal doses.

How Uptravi works in the body

Selexipag is a drug that helps treat pulmonary arterial hypertension. It works by activating a receptor in the lungs that increases production of a molecule called prostacyclin. This molecule has multiple effects, like increasing blood flow, reducing inflammation, and preventing blood clotting. Selexipag is chemically different from prostacyclin itself, and it is also better at activating the receptor. After it is taken in the body, it is broken down into an active metabolite that is even more effective. This metabolite only affects the prostacyclin receptor and has no other effects on the body.

When to interrupt dosage

The proposed dosage of Uptravi is contingent upon the diagnosed condition. The measure additionally fluctuates as per the technique of conveyance (e.g. Tablet, coated - Oral or Tablet, film coated) featured in the accompanying table.

Condition

Dosage

Administration

Pulmonary Arterial Hypertension

, 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1.0 mg, 1.2 mg, 1.4 mg, 1.6 mg, 0.18 mg/mL, 1.8 mg

, Oral, Tablet - Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Warnings

Uptravi has two contraindications, so it should not be employed while suffering from the conditions in the following table.

Uptravi Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Uptravi.

Common Uptravi Drug Interactions

Drug Name

Risk Level

Description

Amifostine

Major

Selexipag may increase the hypotensive activities of Amifostine.

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Selexipag.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Selexipag.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Selexipag.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Selexipag.

Uptravi Toxicity & Overdose Risk

People with severe kidney problems may have up to 70% more exposure to the drug than those with healthy kidneys.

image of a doctor in a lab doing drug, clinical research

Uptravi Novel Uses: Which Conditions Have a Clinical Trial Featuring Uptravi?

53 ongoing trials are studying the utility of Uptravi in providing therapeutic benefit for Pulmonary Arterial Hypertension.

Condition

Clinical Trials

Trial Phases

Pulmonary Arterial Hypertension

0 Actively Recruiting

Uptravi Reviews: What are patients saying about Uptravi?

5

Patient Review

4/14/2021

Uptravi for Pulmonary Arterial Hypertension

This medication has been a lifesaver for me. I was taking Opsumit and Adempas, which helped with my breathing, but the pressure in the right side of my heart was still very high. After taking Uptravi 200mcg once daily, my right side blood pressure has returned to normal levels. I'm so grateful for this medication!

4

Patient Review

9/9/2017

Uptravi for Pulmonary Arterial Hypertension

I started out taking 200 mcg twice a day, and eventually worked up to 1400 mcg twice a day. However, I had to back down to 1200 mcg because of the side effects which include headaches, neck/shoulder/extremity pain, and diarrhea. Even at this lower dosage though, I've found that the drug makes it easier to breathe and gives me more energy and ambition.

3

Patient Review

10/3/2016

Uptravi for Pulmonary Arterial Hypertension

I started at a lower dose and have slowly been working my way up. I'm currently experiencing some headaches and body aches, but hopefully this will improve as I continue to increase the dosage.

2

Patient Review

11/7/2021

Uptravi for Pulmonary Arterial Hypertension

They kept upping the dosage each week, and it made me so nauseous that I had to stop taking it. It was a really terrible experience.

1.7

Patient Review

4/30/2018

Uptravi for Pulmonary Arterial Hypertension

The side effects of this treatment are beyond horrible. The pain is excruciating and feels like my muscles are being slowly pulled apart.

1

Patient Review

10/1/2019

Uptravi for Pulmonary Arterial Hypertension

Hardly any benefits and many drawbacks. Ifound it difficult to breathe, my body hurt more, and I had less energy.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about uptravi

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What class of drug is UPTRAVI?

"Uptravi is a medication used to treat Pulmonary Arterial Hypertension. Uptravi works by relaxing the blood vessels in your lungs which lowers your blood pressure. Uptravi may be used alone or in combination with other medications."

Answered by AI

What is UPTRAVI used for?

"UPTRAVI® is a prescription medication used to treat pulmonary arterial hypertension (a condition characterized by high blood pressure in the arteries of the lungs). UPTRAVI® can help to slow the progression of the disease and reduce the risk of hospitalization for PAH."

Answered by AI

Does UPTRAVI lower blood pressure?

"This medication lowers blood pressure by widening blood vessels in your lungs. It is used to treat pulmonary arterial hypertension and can help prevent your condition from worsening or reduce your risk of needing to be hospitalized."

Answered by AI

Is UPTRAVI FDA approved?

"- Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved UPTRAVI® (selexipag) for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients."

Answered by AI